2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · Real-Time Price · USD
3.140
+0.220 (7.53%)
Dec 20, 2024, 4:00 PM EST - Market closed
2seventy bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for 2seventy bio stock have an average target of 10.4, with a low estimate of 5.00 and a high estimate of 18. The average target predicts an increase of 231.21% from the current stock price of 3.14.
Analyst Consensus: Buy
* Price targets were last updated on Jul 29, 2024.
Analyst Ratings
The average analyst rating for 2seventy bio stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +91.08% | Jul 29, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +59.24% | Jun 27, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +250.32% | May 9, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +282.17% | Apr 8, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +59.24% | Mar 18, 2024 |
Financial Forecast
Revenue This Year
49.18M
from 100.39M
Decreased by -51.01%
Revenue Next Year
66.93M
from 49.18M
Increased by 36.09%
EPS This Year
-0.98
from -4.42
EPS Next Year
-0.51
from -0.98
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 58.5M | 94.4M | 109.3M | |||
| Avg | 49.2M | 66.9M | 89.6M | |||
| Low | 40.2M | 46.4M | 59.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -41.7% | 91.9% | 63.3% | |||
| Avg | -51.0% | 36.1% | 33.9% | |||
| Low | -60.0% | -5.8% | -11.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.76 | -0.09 | 0.13 |
| Avg | -0.98 | -0.51 | -0.21 |
| Low | -1.20 | -0.97 | -0.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.